Protagonist Therapeutics (PTGX) Earnings Date, Estimates & Call Transcripts

$46.32

-0.70 (-1.49%)

(As of 01:53 PM ET)

Upcoming Earnings Date: Nov. 7Estimated
Actual EPS (Aug. 6): -$0.50
Consensus EPS (Aug. 6): -$0.50

PTGX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PTGX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Market JAR

BREAKING NEWS: AI Tech Now Used to Stop School Shooters

Two seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.

Don't miss out. Get the full details on this AI bargain.

Protagonist Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	1	$3.75	$3.75	$3.75
Q2 2024	1	($0.64)	($0.64)	($0.64)
Q3 2024	1	($0.64)	($0.64)	($0.64)
Q4 2024	1	($0.68)	($0.68)	($0.68)
FY 2024	4	$1.79	$1.79	$1.79
Q1 2025	1	($0.69)	($0.69)	($0.69)
Q2 2025	1	$2.09	$2.09	$2.09
Q3 2025	1	($0.54)	($0.54)	($0.54)
Q4 2025	1	$0.88	$0.88	$0.88
FY 2025	4	$1.74	$1.74	$1.74

PTGX Earnings Date and Information

Protagonist Therapeutics last issued its quarterly earnings results on August 6th, 2024. The reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). The company had revenue of $4.17 million for the quarter, compared to the consensus estimate of $40 million. Protagonist Therapeutics has generated $2.44 earnings per share over the last year ($2.44 diluted earnings per share) and currently has a price-to-earnings ratio of 19.0. Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.31 to ($1.35) per share. Protagonist Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off prior year's report dates.

Protagonist Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/7/2024 (Estimated)	-	-	-	-	-	-	-
8/6/2024	-	($0.50)	($0.50)	-	($0.50)	$40.00 million	$4.17 million
5/7/2024	Q1 2024	$2.51	$3.26	+$0.75	$3.26	$300.00 million	$254.95 million
2/27/2024	Q4 2023	$0.05	$0.44	+$0.39	$0.44	$60.00 million	$60.00 million
11/2/2023	Q3 2023	($0.68)	($0.58)	+$0.10	($0.58)	-	-
8/3/2023	Q2 2023	($0.65)	($0.68)	($0.03)	($0.68)	-	-
5/4/2023	Q1 2023	($0.69)	($0.67)	+$0.02	($0.67)	-	-
Get the Latest News and Ratings for PTGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
3/15/2023	Q4 2022	($0.67)	($0.69)	($0.02)	($0.69)	-	-
11/8/2022	Q3 2022	($0.94)	($0.64)	+$0.30	($0.64)	-	-
8/4/2022	Q2 2022	($0.99)	($0.84)	+$0.15	($0.84)	$2.30 million	$0.86 million
5/4/2022	Q1 2022	($0.67)	($0.43)	+$0.24	($0.43)	$19.33 million	$25.72 million
2/28/2022	Q4 2021	($0.79)	($0.77)	+$0.02	($0.77)	$7.38 million	$8.62 million
11/3/2021	Q3 2021	($0.67)	($0.70)	($0.03)	($0.70)	$3.43 million	$10.29 million
8/4/2021	Q2 2021	($0.55)	($0.69)	($0.14)	($0.69)	$5.60 million	$2.27 million
5/4/2021	Q1 2021	($0.57)	($0.54)	+$0.03	($0.54)	$3.75 million	$6.19 million
3/10/2021	Q4 2020	($0.48)	($0.48)	-	($0.48)	$3.38 million	$5.65 million
11/4/2020	Q3 2020	($0.61)	($0.21)	+$0.40	($0.21)	$3.80 million	$13.11 million
8/6/2020	Q2 2020	($0.57)	($0.59)	($0.02)	($0.59)	$3.80 million	$6.22 million
5/7/2020	Q1 2020	($0.69)	($0.72)	($0.03)	($0.72)	$3.60 million	$3.65 million
3/10/2020	Q4 2019	($0.65)	($0.63)	+$0.02	($0.63)	$5.25 million	$2.72 million
11/6/2019	Q3	($0.71)	($0.61)	+$0.10	($0.61)	$5.75 million	$4.14 million

Protagonist Therapeutics Earnings - Frequently Asked Questions

When is Protagonist Therapeutics's earnings date?: Protagonist Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates. Learn more on PTGX's earnings history.
Did Protagonist Therapeutics beat their earnings estimates last quarter?: In the previous quarter, Protagonist Therapeutics (NASDAQ:PTGX) reported ($0.50) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.50). Learn more on analysts' earnings estimate vs. PTGX's actual earnings.
How can I listen to Protagonist Therapeutics's earnings conference call?: The conference call for Protagonist Therapeutics's latest earnings report can be listened to online. Listen to Conference Call
How can I read Protagonist Therapeutics's conference call transcript?: The conference call transcript for Protagonist Therapeutics's latest earnings report can be read online. Read Transcript
How much revenue does Protagonist Therapeutics generate each year?: Protagonist Therapeutics (NASDAQ:PTGX) has a recorded annual revenue of $60 million.
How much profit does Protagonist Therapeutics generate each year?: Protagonist Therapeutics (NASDAQ:PTGX) has a recorded net income of -$78.96 million. PTGX has generated $2.44 earnings per share over the last four quarters.
What is Protagonist Therapeutics's price-to-earnings ratio?: Protagonist Therapeutics (NASDAQ:PTGX) has a trailing price-to-earnings ratio of 18.98 and a forward price-to-earnings ratio of 20.05.
What is Protagonist Therapeutics's EPS forecast for next year?: Protagonist Therapeutics's earnings are expected to decrease from $2.31 per share to ($1.35) per share in the next year.